CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BCBLBRS2305035PrognosticSupportsBetter OutcomeLung Non-small Cell CarcinomaLi et al., 2016
BPRDM1MUTATIONPrognosticSupportsPoor OutcomeDiffuse Large B-cell LymphomaXia et al., 2017
BKRASMutationPredictiveSupportsSensitivity/ResponseHepatocellular CarcinomaSorafenib,RefametinibLim et al., 2014
CMETExon 14 Skipping MutationPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaCrizotinibShea et al., 2016
CMETD1228NPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibHeist et al., 2016
CBRAF::CUL1FusionPredictiveSupportsSensitivity/ResponseOvarian Serous CarcinomaMitogen-Activated Protein Kinase Kinase InhibitorGrisham et al., 2015
CKIAA1549::BRAFFusionPredictiveSupportsSensitivity/ResponseSpindle Cell SarcomaSorafenib,Bevacizumab,TemsirolimusSubbiah et al., 2014
CPIK3CAE545KPredictiveSupportsResistanceLung AdenocarcinomaErlotinib,GefitinibBelchis et al., 2016
BVHLMutationPredictiveDoes Not SupportSensitivity/ResponseRenal Cell CarcinomaPazopanibChoueiri et al., 2013
BEPAS1OverexpressionPredictiveDoes Not SupportSensitivity/ResponseRenal Cell CarcinomaPazopanibChoueiri et al., 2013
BHIF1AEXPRESSIONPredictiveDoes Not SupportSensitivity/ResponseRenal Cell CarcinomaPazopanibChoueiri et al., 2013
ECDH1MUTATIONPrognosticSupportsPoor OutcomeStomach CarcinomaRokutan et al., 2016
ERHOAMUTATIONPrognosticSupportsPoor OutcomeStomach CarcinomaRokutan et al., 2016
BERBB2AmplificationPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabMartin et al., 2013
CERBB2AmplificationPredictiveSupportsSensitivity/ResponseScrotum Paget's DiseaseTrastuzumabBarth et al., 2015
CMEN1FRAMESHIFT TRUNCATIONDiagnosticSupportsPositiveOncocytic Carcinoma Of The ThyroidKasaian et al., 2015
CBRAFV600EPredictiveSupportsSensitivity/ResponseMultiple MyelomaVemurafenibSharman et al., 2014
DNRASMutationPredictiveSupportsResistanceColorectal CancerCetuximabBertotti et al., 2011
DBRAFMutationPredictiveSupportsResistanceColorectal CancerCetuximabBertotti et al., 2011
DHGFEXPRESSIONPredictiveSupportsSensitivity/ResponseGlioblastomaMET Tyrosine Kinase Inhibitor SGX523Xie et al., 2012
BEGFRExpressionPredictiveSupportsSensitivity/ResponseColorectal CancerPanitumumabVan Cutsem et al., 2007
CMETAmplificationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCrizotinibCaparica et al., 2017
CKRASG12VPredictiveDoes Not SupportResistanceCancerCrizotinibPalma et al., 2014
BPRDM1MUTATIONPrognosticSupportsPoor OutcomeDiffuse Large B-cell LymphomaXia et al., 2017
CERRFI1E384*PredictiveSupportsSensitivity/ResponseCholangiocarcinomaErlotinibBorad et al., 2014
DESR1S463PPredictiveSupportsResistanceEstrogen-receptor Positive Breast CancerAromatase InhibitorToy et al., 2013
DCCNE1OverexpressionPredictiveSupportsSensitivity/ResponseOvarian CancerCDK Inhibitor SNS-032Yang et al., 2015
DBRAFG596CPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDabrafenib,TrametinibNoeparast et al., 2017
DSMARCB1UnderexpressionPredictiveSupportsSensitivity/ResponseSynovial SarcomaTazemetostatKawano et al., 2016
BSH2B3RS3184504PredisposingSupportsPredispositionColorectal CancerCheng et al., 2015
BEWSR1::FLI1FusionDiagnosticSupportsPositiveEwing Sarcoma Of BonePark et al., 1998
CTSC1R1062WPredisposingSupportsUncertain SignificanceTuberous SclerosisQin et al., 2010
BEGFRG719PredictiveSupportsSensitivity/ResponseLung AdenocarcinomaErlotinibKlughammer et al., 2016
CFUS::DDIT3FusionDiagnosticSupportsPositiveMyxoid LiposarcomaSreekantaiah et al., 1992
DERBB3V855APredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAfatinib,PertuzumabUmelo et al., 2016
BCHEK2IVS2+1G>APredisposingDoes Not SupportPredispositionProstate CancerWang et al., 2015
CVHLA56fs (c.164_165insA)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseCrossey et al., 1994
CVHLE55= (c.165G>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOlschwang et al., 1998
DRRM1OverexpressionPredictiveSupportsResistancePancreatic CancerGemcitabineNakano et al., 2007
DRRM2OVEREXPRESSIONPredictiveSupportsResistancePancreatic CancerGemcitabineNakano et al., 2007
BRB1MutationPredictiveSupportsSensitivity/ResponseLung Small Cell CarcinomaChemotherapyDowlati et al., 2016
CETV6::NTRK3FusionPredictiveDoes Not SupportSensitivity/ResponseMammary Analogue Secretory CarcinomaCrizotinibDrilon et al., 2016
DCDKN2ALossPredictiveSupportsSensitivity/ResponseEwing SarcomaPalbociclib,LinsitinibMurakami et al., 2016
DCDKN2BLossPredictiveSupportsSensitivity/ResponseEwing SarcomaLinsitinib,PalbociclibMurakami et al., 2016
DCDKN2ALossPredictiveSupportsSensitivity/ResponseDermatofibrosarcoma ProtuberansPalbociclibEilers et al., 2015
CRUNX1T148HFSX9PredisposingSupportsUncertain SignificanceAcute Myeloid LeukemiaBéri-Dexheimer et al., 2008
BERBB2Y772_A775DUPPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaDacomitinibKris et al., 2015
CBRAFV600E AND GNAS R201CPredictiveSupportsResistanceColorectal CancerIrinotecan,Vemurafenib,CetuximabHong et al., 2016
BFGFR1AmplificationPredictiveDoes Not SupportResistanceBreast CancerInfigratinibNogova et al., 2017
CFGFR1AmplificationPredictiveDoes Not SupportSensitivity/ResponseBladder CarcinomaInfigratinibNogova et al., 2017
Page 73 of 96
PreviousNext